Free Trial
ASX:PXS

Pharmaxis (PXS) Stock Price, News & Analysis

Pharmaxis logo

About Pharmaxis Stock (ASX:PXS)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
721,139 shs
Average Volume
N/A
Market Capitalization
A$20.23 million
P/E Ratio
N/A
Dividend Yield
6.41%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharmaxis and its competitors with MarketBeat's FREE daily newsletter.

PXS Stock News Headlines

Canaccord Genuity Sticks to Their Buy Rating for Pharmaxis Ltd (SNT)
Pharmaxis Ltd Highlights Product Pipeline and Risks
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Syntara bolsters financial position with R&D tax incentive
FIVE at FIVE AU: ASX down 1.5% on Middle East fears; employment slows
Pharmaxis to focus on clinical-stage drug development
See More Headlines

PXS Stock Analysis - Frequently Asked Questions

Pharmaxis Ltd (ASX:PXS) issued its earnings results on Thursday, February, 14th. The company reported ($0.03) earnings per share for the quarter. Pharmaxis had a negative net margin of 161.24% and a negative trailing twelve-month return on equity of 143.13%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pharmaxis investors own include Atara Biotherapeutics (ATRA), CRISPR Therapeutics (CRSP), Acasti Pharma (ACST), American Woodmark (AMWD), Guardion Health Sciences (GHSI), Incannex Healthcare (IHL) and XPO (XPO).

Company Calendar

Last Earnings
2/14/2019
Today
7/09/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
Transportation
Current Symbol
ASX:PXS
CIK
N/A
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
0.21
Net Income
-A$18.43 million
Net Margins
-161.24%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
A$11.89 million
Price / Cash Flow
1.32
Book Value
A$0.00 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
A$20.23 million
Optionable
Not Optionable
Beta
0.64
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (ASX:PXS) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners